



Zymeworks Appoints Dr. Michael J. Gresser to its Scientific Advisory Board

October 14th, 2008

VANCOUVER, British Columbia, Canada – Zymeworks Inc., a privately held computational biotechnology company, today announced it has added Dr. Michael J. Gresser to its scientific advisory board.

“The addition of Mike to Zymeworks’ scientific advisory board is invaluable,” says Dr. Ali Tehrani, President and CEO of Zymeworks Inc. “As Zymeworks continues to move towards the in-licensing and optimization of antibody therapeutics and the progression of these candidates towards clinical trials, the Company will benefit significantly from Mike’s expertise and guidance.”

Dr. Gresser is an expert in drug development and the advancement of lead compounds into clinical trials. Most recently he served as Vice President of Research for Inflammation at Amgen, Inc. Previously, Dr. Gresser was the Executive Director of Biochemistry and Molecular Biology at Merck Frosst Center for Therapeutic Research, where he was involved in the development of Singulair® and Vioxx®. Dr. Gresser was a Professor in the Department of Chemistry at the Simon Fraser University, a postdoctoral fellow at the Molecular Biology Institute at UCLA, and received his Ph.D. in Biochemistry from Brandeis University. Dr. Gresser is currently the Chief Scientific Officer (Elect) at Oxford Genome Sciences, a Visiting Scholar at the Molecular Biology Institute at UCLA, and a principal with Clarity Therapeutics Consulting.

About Zymeworks Inc.

Zymeworks is a computational biotechnology company that combines proprietary molecular simulation technology with high performance computing to research and develop protein therapeutics and industrial enzymes. Zymeworks’ proprietary ZymeCAD™ molecular simulation platform creates a highly detailed modeling environment that generates novel physical and chemical insights into protein systems. Zymeworks’ protein engineers utilize these new understandings into structure-function relationships to accurately and predictively modify proteins to address customers’ needs and to advance Zymeworks’ protein therapeutics pipeline. More information on Zymeworks can be found at <http://www.zymeworks.com>.

Contact:

Zymeworks Inc.

Manager, Business Development

604-678-1388, info@zymeworks.com

Source: Zymeworks Inc.